Growth & profitability
- Revenue has grown 73.6% per year over the past 5 years.
- Operating margin has expanded, at 4.5% in the latest year.
HIMS Financials Hims & Hers Health, Inc.
7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $2.3B | $128M | 73.8% | 4.5% | $57M | — | $229M |
| 2024 | $1.5B | $126M | 79.5% | 4.2% | $198M | — | $221M |
| 2023 | $872M | -$24M | 82.0% | -3.4% | $47M | — | $97M |
| 2022 | $527M | -$66M | 77.6% | -13.0% | -$34M | — | $47M |
| 2021 | $272M | -$108M | 75.2% | -42.3% | — | — | $72M |
| 2020 | $149M | -$18M | 73.6% | -10.2% | — | — | $27M |
| 2019 | $83M | -$72M | 54.0% | -90.1% | — | — | $23M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $608M | -$92M | 65.2% | -12.9% | $53M | — | $222M |
| Dec '25 | $618M | $21M | 71.9% | 1.5% | -$3M | — | $229M |
| Sep '25 | $599M | $16M | 73.8% | 2.0% | $79M | — | $346M |
| Jun '25 | $545M | $43M | 76.4% | 4.9% | -$70M | — | $1.1B |
| Mar '25 | $586M | $49M | 73.5% | 9.9% | $50M | — | $274M |
| Dec '24 | $481M | $26M | 76.8% | 3.9% | $59M | — | $221M |
| Sep '24 | $402M | $76M | 79.2% | 5.6% | $79M | — | $166M |
| Jun '24 | $316M | $13M | 81.3% | 3.5% | $48M | — | $129M |
| Mar '24 | $278M | $11M | 82.4% | 3.6% | $12M | — | $105M |
| Dec '23 | $247M | $1M | 82.7% | -0.2% | — | — | $97M |
| Sep '23 | $227M | -$8M | 82.6% | -3.8% | — | — | $58M |
| Jun '23 | $208M | -$7M | 81.8% | -4.4% | — | — | $65M |
| Mar '23 | $191M | -$10M | 80.4% | -5.9% | — | — | $49M |
| Dec '22 | $167M | -$11M | 79.1% | -6.9% | — | — | $47M |
| Sep '22 | $145M | -$19M | 79.0% | -13.8% | — | — | $58M |
| Jun '22 | $114M | -$20M | 76.8% | -17.8% | — | — | $55M |
| Mar '22 | $101M | -$16M | 73.8% | -16.7% | — | — | $48M |
| Dec '21 | $85M | -$31M | 73.3% | -25.5% | — | — | $72M |
| Sep '21 | $74M | -$16M | 74.0% | -37.3% | — | — | $65M |
| Jun '21 | $61M | -$9M | 77.9% | -28.7% | — | — | $107M |
Valuation over time
How the market has priced HIMS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 43.8× (Dec '24) to 58.2× (Jun '26).
- The price-to-sales ratio has fallen from 4.3× (Mar '23) to 3.2× (Jun '26).
P/E
P/S
Frequently asked questions
Is HIMS growing its revenue and profit?
Over the past 5 years, Hims & Hers Health, Inc.'s revenue has grown 73.6% per year. These are computed facts, not advice.
How much debt does HIMS have?
As of FY2025, Hims & Hers Health, Inc. reported — of total debt against $229M of cash.
What is HIMS's profit margin?
In FY2025, gross margin was 73.8%, operating margin 4.5%, and net margin 5.5%.
What is HIMS's P/E ratio?
As of Jun '26, Hims & Hers Health, Inc. traded at a price-to-earnings ratio of about 58.2× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.